Acurx Pharmaceuticals Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Acurx Pharmaceuticals (ACXP) reported its Q3 2025 financial results, showing improved cash reserves of $5.9 million, up from $3.7 million in 2024. The company incurred a net loss of $1.99 million, down from $2.82 million year-over-year, with total operating expenses reduced to $2.03 million. Acurx raised $7.8 million through financing activities and is focused on advancing its lead product, ibezapolstat, while acknowledging the need for further funding to achieve profitability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments